Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative 18F-FDG PET/CT analysis

EJNMMI Research

Table 1 Patient characteristics

Characteristic	All patients (n = 64)
Gender
Male	40 (62.5%)
Female	24 (37.5%)
Age (years) at baseline PET/CT	59 (45–69) (range 25–80)
World Health Organization performance
0	45 (70.3%)
1	7 (10.9%)
≥ 2	7 (11.0%)
Missing	5 (7.8%)
Histology primary melanoma
Cutaneous	47 (73.4%)
Mucosal	4 (6.3%)
Primary melanoma unknown/missing	13 (20.3%)
M-stage at baseline PET/CT
M1a	1 (1.6%)
M1b	2 (3.1%)
M1c	61 (95.3%)
No. of different metastatic locations^a
1	3 (4.7%)
2	6 (9.4%)
> 2	55 (85.9%)
Organ involvement
(Sub)cutaneous	39 (60.9%)
Lymph nodes	54 (84.4%)
Lungs	40 (62.5%)
Muscular	25 (39.1%)
Skeletal	39 (60.9%)
Liver	24 (37.5%)
Abdomen^b	30 (46.9%)
Other^c	14 (21.9%)
Brain metastases^d
Yes	22 (34.4%)
¹⁸F-FDG-avid^e	11 (17.2%)
Not ¹⁸F-FDG-avid	11 (17.2%)
No	35 (54.7%)
Missing	7 (10.9%)
BRAF mutation status
BRAF^V600 mutation	31 (48.4%)
No BRAF^V600 mutation	33 (51.6%)
RAS mutation status
RAS mutation^f	15 (23.4%)
No RAS mutation	49 (76.6%)
Baseline serum LDH (U/l)	246 (192–327) (range 92–11,371)
Normal	35 (54.7%)
Elevated^g	28 (43.7%)
> 1–2× ULN	23 (35.9%)
> 2× ULN	5 (7.8%)
Missing	1 (1.6%)
Interval between baseline PET/CT and LDH measurement (days)	0 (− 7 to + 3) (range − 39 to + 11)

Data are displayed as n (%) or median (interquartile range)
LDH lactate dehydrogenase, ULN upper limit of normal
^aIncluding brain metastases
^bNumber of patients with lesions in the abdominal cavity/peritoneum (n = 27; 42.2% of all patients), adrenal gland (n = 12; 18.8%), bowel (n = 6; 9.4%), spleen (n = 3; 4.7%), kidney (n = 2; 3.1%), gallbladder (n = 1; 1.6%), stomach (n = 1; 1.6%), rectum (n = 1; 1.6%) and/or pancreas (n = 1; 1.6%)
^cNumber of patients with lesions in the vaginal or nasal mucosa (n = 4; 6.3%), myelum (n = 1; 1.6%), shoulder joint (n = 2; 3.1%), breast (n = 2; 3.1%), pericardium (n = 3; 4.7%), heart (n = 2; 3.1%) and/or abdominal or thoracic wall of undetermined tissue of origin (n = 2; 3.1%)
^dBased on MRI brain (n = 53) or, when missing, contrast enhanced CT (n = 4)
^eI.e. distinguishable from normal brain tissue
^fNRAS (n = 14) and KRAS (n = 1)
^gI.e. > 250 U/l